Literature DB >> 18176661

5-HT2C receptor agonists as an innovative approach for psychiatric disorders.

Sharon Rosenzweig-Lipson1, John Dunlop, Karen L Marquis.   

Abstract

Modulating activity at the 5-HT(2C) receptor holds a tremendous amount of therapeutic promise in multiple psychiatric indications. However, the signaling and regulation of the 5-HT(2C) receptor is highly complex due to multiple signaling pathways and agonist-directed trafficking of this receptor. Moreover, the 5-HT(2C) receptor is differentially regulated via RNA editing in multiple psychiatric disorders and following either pharmacological or environmental manipulation. Direct and indirect data suggest that both agonists and antagonists may provide benefits in several disorders. The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT(2C) agonists in the treatment of both schizophrenia and depressive disorders. Copyright 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18176661     DOI: 10.1358/dnp.2007.20.9.1162244

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  11 in total

Review 1.  When you can't trust the DNA: RNA editing changes transcript sequences.

Authors:  Volker Knoop
Journal:  Cell Mol Life Sci       Date:  2010-10-12       Impact factor: 9.261

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

3.  Agomelatine for Depression in Schizophrenia: A Case-Series.

Authors:  Jochen Mutschler; Nicolas Rüsch; Herdis Schönfelder; Uwe Herwig; Annette B Brühl; Martin Grosshans; Wulf Rössler; Heike Russmann
Journal:  Psychopharmacol Bull       Date:  2012-02-15

4.  Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.

Authors:  Kathryn A Cunningham; Robert G Fox; Noelle C Anastasio; Marcy J Bubar; Sonja J Stutz; F Gerard Moeller; Scott R Gilbertson; Sharon Rosenzweig-Lipson
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

5.  Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.

Authors:  Eleanor H Simpson; Christoph Kellendonk; Ryan D Ward; Vanessa Richards; Olga Lipatova; Stephen Fairhurst; Eric R Kandel; Peter D Balsam
Journal:  Biol Psychiatry       Date:  2011-03-16       Impact factor: 13.382

6.  Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects.

Authors:  Vanja Duric; Mounira Banasr; Craig A Stockmeier; Arthur A Simen; Samuel S Newton; James C Overholser; George J Jurjus; Lesa Dieter; Ronald S Duman
Journal:  Int J Neuropsychopharmacol       Date:  2012-02-17       Impact factor: 5.176

7.  Synthesis and Evaluation of Pyridyloxypyridyl Indole Carboxamides as Potential PET Imaging Agents for 5-HT2C Receptors.

Authors:  Fanxing Zeng; Jonathon A Nye; Ronald J Voll; Leonard Howell; Mark M Goodman
Journal:  ACS Med Chem Lett       Date:  2018-02-05       Impact factor: 4.345

8.  Synthesis and evaluation of methylated arylazepine compounds for PET imaging of 5-HT(2c) receptors.

Authors:  Michael L Granda; Stephen M Carlin; Christian K Moseley; Ramesh Neelamegam; Joseph B Mandeville; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

9.  Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

Authors:  Clinton E Canal; Raymond G Booth; Drake Morgan
Journal:  Neuropharmacology       Date:  2013-01-23       Impact factor: 5.250

10.  Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients.

Authors:  Vatsalya Vatsalya; Maiying Kong; Luis M Marsano; Zimple Kurlawala; Kan V Chandras; Melanie L Schwandt; Vijay A Ramchandani; Craig J McClain
Journal:  Subst Abuse       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.